Achieving Optimal Medical Therapy: Insights From the ORBITA Trial

Foley, Michael and Rajkumar, Christopher A. and Shun‐Shin, Matthew and Ganesananthan, Sashiananthan and Seligman, Henry and Howard, James and Nowbar, Alexandra N. and Keeble, Thomas R. and Davies, John R. and Tang, Kare H. and Gerber, Robert and O’Kane, Peter and Sharp, Andrew S. P. and Petraco, Ricardo and Malik, Iqbal S. and Nijjer, Sukhjinder and Sen, Sayan and Francis, Darrel P. and Al-Lamee, Rasha (2021) Achieving Optimal Medical Therapy: Insights From the ORBITA Trial. Journal of the American Heart Association, 10 (3). e017381. ISSN 2047-9980

[img]
Preview
Text
Published Version
Available under the following license: Creative Commons Attribution.

Download (1MB) | Preview
Official URL: https://doi.org/10.1161/JAHA.120.017381

Abstract

Background: In stable coronary artery disease, medications are used for 2 purposes: cardiovascular risk reduction and symptom improvement. In clinical trials and clinical practice, medication use is often not optimal. The ORBITA (Objective Randomised Blinded Investigation With Optimal Medical Therapy of Angioplasty in Stable Angina) trial was the first placebo-controlled trial of percutaneous coronary intervention. A key component of the ORBITA trial design was the inclusion of a medical optimization phase, aimed at ensuring that all patients were treated with guideline-directed truly optimal medical therapy. In this study, we report the medical therapy that was achieved. Methods and Results: After enrollment into the ORBITA trial, all 200 patients entered a 6-week period of intensive medical therapy optimization, with initiation and uptitration of risk reduction and antianginal therapy. At the prerandomization stage, the median number of antianginals established was 3 (interquartile range, 2-4). A total of 195 patients (97.5%) reached the prespecified target of ≥2 antianginals; 136 (68.0%) did not stop any antianginals because of adverse effects, and the median number of antianginals stopped for adverse effects per patient was 0 (interquartile range, 0-1). Amlodipine and bisoprolol were well tolerated (stopped for adverse effects in 4/175 [2.3%] and 9/167 [5.4%], respectively). Ranolazine and ivabradine were also well tolerated (stopped for adverse effects in 1/20 [5.0%] and 1/18 [5.6%], respectively). Isosorbide mononitrate and nicorandil were stopped for adverse effects in 36 of 172 (20.9%) and 32 of 141 (22.7%) of patients, respectively. Statins were well tolerated and taken by 191 of 200 (95.5%) patients. Conclusions: In the 12-week ORBITA trial period, medical therapy was successfully optimized and well tolerated, with few drug adverse effects leading to therapy cessation. Truly optimal medical therapy can be achieved in clinical trials, and translating this into longer-term clinical practice should be a focus of future study. Registration URL: https://www.clinicaltrials.gov; Unique identifier: NCT02062593.

Item Type: Journal Article
Keywords: adverse effects, angina, compliance/adherence, medical therapy, randomized controlled trial
Faculty: Faculty of Health, Education, Medicine & Social Care
Depositing User: Ian Walker
Date Deposited: 28 Jan 2021 14:30
Last Modified: 22 Apr 2021 15:01
URI: https://arro.anglia.ac.uk/id/eprint/706231

Actions (login required)

Edit Item Edit Item